The Biologics Prescribers Collaborative aims to ensure that sound policies are in place to promote the safest possible use of all biologics, including biosimilars, for all patients.

About Us

As groups representing physicians who regularly prescribe biologics, we have a unique and important perspective about the use of these medicines. While biosimilars hold tremendous promise to increase access and affordability of these advanced medicines, their availability will increase the complexity of the treatment landscape. As such, the Biologics Prescribers Collaborative aims to ensure that sound policies are in place to promote the safest possible use of all biologics, including biosimilars, for all patients.

More About Us

Our Guiding Principles 

The Biologics Prescribers Collaborative’s mission is to ensure that physicians who prescribe complex biologic treatments are given a voice in discussions shaping policies that govern the use of biosimilars. Learn more about our four guiding principles and how we plan to achieve a unified prescriber voice.

Read Our Principles

Resources

View All ›

November 9, 2016

Importance of “Meaningful” Suffixes

Meaningful suffixes are important in medicine. That’s why 80% of doctors prefer them for biosimilar naming as well. The FDA is considering naming biosimilar medicines with a random code versus a more recognizable name. In a recent SERMO* poll, representing over 500 physicians across multiple specialties, 80% of physicians prefer a “meaningful suffix.” Physician groups across the country call for biosimilar names that are easily distinguished and recognized.  *SERMO is the largest global social network exclusively for doctors. Read More ›

October 18, 2016

BPC Supports FDA on BsUFA Proposal, Raises Guidance Timing Concerns

BPC supports FDA's continuing careful deliberation on biosimilar-related issues along with your expert and diligent review of medical products. In particular, the Collaborative is pleased that FDA has stated that it will make decisions on a case-by-case basis until it has the knowledge to impose a comprehensive regulatory framework for the approval and safe use of biosimilars. BPC realizes that this is a time and resource intensive process. Therefore, we applaud FDA for the proposed recommendations being submitted for the BsUFA reauthorization for FY 2018-2022 and for taking the opportunity to set aggressive drug review timelines and goals, refine existing activities and remove provisions that are no longer needed. Read More ›

September 23, 2016

BPC Statement on FDA Approval of Adalimumab Biosimilar

The Biologics Prescribers Collaborative (BPC) welcomes the U.S. Food and Drug Administration (FDA)'s decision today to approve Amjevita, the fourth biosimilar in the United States and an Amgen biosimilar to AbbVie’s Humira (adalimumab). This approval represents an important step towards realizing the promise of biosimilars to expand patient access to these lifesaving therapies. BPC appreciates FDA's continuing careful deliberation on biosimilar-related issues, however the decision approve a fourth biosimilar without FDA finalizing their decisions on naming, labeling or interchangeability policies for biologics does cause concern and creates confusion. Read More ›

Stay Informed

Stay updated! For more information about the Biologics Prescribers Collaborative, please fill out the following information.